Stock GABA GABATHER AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gabather AB

Equities

GABA

SE0010869552

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 13:38:29 31/05/2024 BST 		5-day change 1st Jan Change
1.655 SEK +6.09% Intraday chart for Gabather AB +6.77% +17.38%
04-10 Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002 CI
03-18 Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 74.36 66.48 26.8 75.06 60.74 61.73
Enterprise Value (EV) 1 37.61 49.83 -18.1 44.14 45.89 55.46
P/E ratio -10.5 x -3.27 x -4.86 x -5.09 x -3.57 x -7.21 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -3.81 x -2.47 x 1.28 x -3.01 x -2.71 x -
EV / FCF -3.77 x -3.99 x 2.15 x -5.22 x -4.71 x -8.67 x
FCF Yield -26.5% -25% 46.4% -19.2% -21.2% -11.5%
Price to Book 2.27 x 4.19 x 1.6 x 2.6 x 5.54 x 18 x
Nbr of stocks (in thousands) 3,681 5,153 5,153 13,403 13,408 13,627
Reference price 2 20.20 12.90 5.200 5.600 4.530 4.530
Announcement Date 23/04/18 29/03/19 01/04/20 26/03/21 27/03/22 10/05/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -9.872 -20.2 -14.19 -14.67 -16.91 -
EBIT 1 -9.937 -20.29 -14.27 -14.75 -16.99 -8.551
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -9.938 -20.31 -14.28 -14.74 -17 -8.548
Net income 1 -9.938 -20.31 -14.28 -14.74 -17 -8.548
Net margin - - - - - -
EPS 2 -1.920 -3.940 -1.070 -1.100 -1.270 -0.6283
Free Cash Flow 1 -9.979 -12.48 -8.401 -8.457 -9.744 -6.393
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 23/04/18 29/03/19 01/04/20 26/03/21 27/03/22 10/05/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 36.7 16.6 44.9 30.9 14.8 6.27
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -9.98 -12.5 -8.4 -8.46 -9.74 -6.39
ROE (net income / shareholders' equity) -25.2% -78.1% -48% -40.7% -87.4% -119%
ROA (Net income/ Total Assets) -15% -44.7% -27.8% -23.6% -45.6% -48.3%
Assets 1 66.34 45.47 51.41 62.56 37.3 17.71
Book Value Per Share 2 8.880 3.080 3.250 2.150 0.8200 0.2500
Cash Flow per Share 2 7.130 3.230 3.350 2.310 1.110 0.4600
Capex - - - 0.29 - -
Capex / Sales - - - - - -
Announcement Date 23/04/18 29/03/19 01/04/20 26/03/21 27/03/22 10/05/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GABATHER AB Stock Gabather AB
+17.38% 2.97M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GABA Stock
  4. Financials Gabather AB